<p>JonesTrading 分析师 Boris Peaker 维持了对 ELVN 股票的看涨态度，昨日给予买入评级。</p>
<h3>在 TipRanks 上享受 55% 的折扣</h3>
<ul>
<li>解锁对冲基金级别的数据和强大的投资工具，以做出更聪明、更精准的决策</li>
<li>发现表现优异的股票投资理念，并升级到市场领先者的投资组合，使用智能投资者精选</li>
</ul>
<p>Boris Peaker 给予买入评级的原因包括对 ELVN-001 在之前接受过 Scemblix 的晚期慢性髓性白血病患者的鼓舞人心的临床数据。这款药物显示出强劲的分子反应率、持久的反应时间以及良好的耐受性，仅有适度的停药率，增强了对其治疗价值的信心。</p>
<p>Peaker 还认为 ELVN-001 的 ATP 结合口袋机制和在重度预处理患者中的疗效是其相较于竞争药物如 TERN-701 和现有 ATP 抑制剂的差异化优势。结合公司稳健的现金状况、在 2L/2L+ 环境中的明确战略机会以及不变的 45 美元目标价，这些因素支撑了他对该股票的积极展望，并证明维持买入推荐的合理性。</p>
<p>Peaker 关注医疗保健行业，重点分析如 Relay Therapeutics、Enliven Therapeutics 和 Nuvation Bio 等股票。根据 TipRanks，Peaker 的平均回报率为 20.3%，推荐股票的成功率为 45.78%。</p>
<p>在昨日发布的另一份报告中，Guggenheim 也对该股票进行了覆盖，给予买入评级，目标价为 80.00 美元。</p>

ELVN

<p>乔恩斯交易公司的 Boris Peaker 重申了对 ELVN-001 的买入评级，维持 45 美元的目标价，原因是强劲的临床数据和战略定位。这款药物在晚期慢性髓性白血病患者中显示出有希望的分子反应率和耐受性。Peaker 强调了 ELVN-001 与竞争对手相比独特的机制和疗效，以及公司稳健的现金状况。古根海姆也开始覆盖该股票，给予买入评级和 80 美元的目标价。Peaker 在他的股票推荐中平均回报率为 20.3%，成功率为 45.78%</p>

<p>JonesTrading analyst Boris Peaker has maintained their bullish stance on ELVN stock, giving a Buy rating yesterday.</p>
<div class="lb-trans"><p>JonesTrading 分析师 Boris Peaker 维持了对 ELVN 股票的看涨态度，昨日给予买入评级。</p>
</div><h3>Claim 55% Off TipRanks</h3>
<div class="lb-trans"><h3>在 TipRanks 上享受 55% 的折扣</h3>
</div><ul>
<li>Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions</li>
<li>Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks</li>
</ul>
<div class="lb-trans"><ul>
<li>解锁对冲基金级别的数据和强大的投资工具，以做出更聪明、更精准的决策</li>
<li>发现表现优异的股票投资理念，并升级到市场领先者的投资组合，使用智能投资者精选</li>
</ul>
</div><p>Boris Peaker has given his Buy rating due to a combination of factors, including encouraging clinical data for ELVN-001 in late-line CML patients who previously received Scemblix. The drug has demonstrated strong molecular response rates, durable responses over time, and a favorable tolerability profile, with only a modest discontinuation rate, supporting confidence in its therapeutic value.</p>
<div class="lb-trans"><p>Boris Peaker 给予买入评级的原因包括对 ELVN-001 在之前接受过 Scemblix 的晚期慢性髓性白血病患者的鼓舞人心的临床数据。这款药物显示出强劲的分子反应率、持久的反应时间以及良好的耐受性，仅有适度的停药率，增强了对其治疗价值的信心。</p>
</div><p>Peaker also views ELVN-001’s ATP-binding pocket mechanism and efficacy in heavily pre-treated patients as differentiating advantages versus competing agents like TERN-701 and existing ATP inhibitors. Combined with the company’s solid cash position, clear strategic opportunity in the 2L/2L+ setting, and an unchanged $45 price target, these elements underpin his positive outlook and justify maintaining a Buy recommendation.</p>
<div class="lb-trans"><p>Peaker 还认为 ELVN-001 的 ATP 结合口袋机制和在重度预处理患者中的疗效是其相较于竞争药物如 TERN-701 和现有 ATP 抑制剂的差异化优势。结合公司稳健的现金状况、在 2L/2L+ 环境中的明确战略机会以及不变的 45 美元目标价，这些因素支撑了他对该股票的积极展望，并证明维持买入推荐的合理性。</p>
</div><p>Peaker covers the Healthcare sector, focusing on stocks such as Relay Therapeutics, Enliven Therapeutics, and Nuvation Bio. According to TipRanks, Peaker has an average return of 20.3% and a 45.78% success rate on recommended stocks.</p>
<div class="lb-trans"><p>Peaker 关注医疗保健行业，重点分析如 Relay Therapeutics、Enliven Therapeutics 和 Nuvation Bio 等股票。根据 TipRanks，Peaker 的平均回报率为 20.3%，推荐股票的成功率为 45.78%。</p>
</div><p>In another report released yesterday, Guggenheim also initiated coverage with a Buy rating on the stock with a $80.00 price target.</p>
<div class="lb-trans"><p>在昨日发布的另一份报告中，Guggenheim 也对该股票进行了覆盖，给予买入评级，目标价为 80.00 美元。</p>
</div>

Boris Peaker Reiterates Buy Rating on ELVN-001 with Unchanged $45 Price Target, Citing Strong Clinical Data and Strategic Positioning

Tip Ranks

Boris Peaker 重申对 ELVN-001 的买入评级，并维持 45 美元的目标价不变，理由是其强劲的临床数据和战略定位